SEARCH

SEARCH BY CITATION

References

  • 1
    Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A 1996; 93: 74953.
  • 2
    Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2: 144551.
  • 3
    Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 92735.
  • 4
    Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 22730.
  • 5
    Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 815.
  • 6
    Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 63740.
  • 7
    Wright GL,Jr., Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 32634.
  • 8
    Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30: 66776.
  • 9
    Bermejo CE, Coursey J, Basler J, Austenfeld M, Thompson I. Histologic confirmation of lesions identified by Prostascint scan following definitive treatment. Urol Oncol 2003; 21: 34952; discussion 53.
  • 10
    Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996; 21: 70413.
  • 11
    Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002; 5: 1325.
  • 12
    Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 171721.
  • 13
    Milowsky MI, Joyce MA, Berger F, Rosmarin AS, Navarro MV, Kostakoglu L, Vallabahajosula S, Goldsmith SJ, Nanus DM, Bander NH. Phase I trial results of Yttrium-90 (90-Y)-labeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody (MAb) J591 in the treatment of patients with advanced prostate cancer (PC) [Abstract 1583]. Proc Am Soc Clin Oncol 2003; 22: 394.
  • 14
    Milowsky MI, Rosmarin AS, Cobham MV, Navarro MV, Keresztes RS, Kostakoglu L, Smith-Jones P, Vallabahajosula S, Kim SW, Liu H, Goldsmith SJ, Bander NH. Anti-PSMA MAb hJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies [Abstract 29]. Proc ASCO 2002.
  • 15
    Morris MJ, Divgi C, Kelly WK. Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced cancers. Proc AACR 2003; 44: 920.
  • 16
    Morris MJ, Divgi C, Larson S. Pilot trial of antibody J591 for castrate metastatic prostate cancer. ASCO Molecular Therapy Symposium 2002.
  • 17
    Morris MJ, Pandit-Taskar N, Divgi C, Warren N, Nacca A, Smith-Jones P, Halpern J, Finn R, Larson S, Scher HI. Pilot trial of anti-PSMA antibody J591 for prostate cancer [Abstract 1634]. Proc ASCO 2003.
  • 18
    Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 2002; 20: 2118.
  • 19
    Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin S, Morales A, Curley T, DeLaCruz A, Webb IJ, Scher HI. Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC). ASCO Annual Meeting 2004.
  • 20
    Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000; 38: 20817.
  • 21
    Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997; 32: 2728.
  • 22
    Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40: 1259.
  • 23
    Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190: 171722.
  • 24
    Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000; 128: 27380.
  • 25
    Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A 1996; 93: 1480914.
  • 26
    Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998; 102: 125864.
  • 27
    Bowne WB, Wolchok JD, Hawkins WG, Srinivasan R, Gregor P, Blachere NE, Moroi Y, Engelhorn ME, Houghton AN, Lewis JJ. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther 1999; 5: 21725.
  • 28
    Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170: 518894.
  • 29
    Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 2002; 102: 13743.
  • 30
    Wolchok JD, Srinivasan R, Perales MA, Houghton AN, Bowne WB, Blachere NE. Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens. Cancer Immunol 2001; 1: 9.
  • 31
    Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 128490.
  • 32
    Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003; 30: 64958.
  • 33
    Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning,expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001; 12: 11723.
  • 34
    Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107: 3239.
  • 35
    Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004; 22: 17008.
  • 36
    Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000; 18: 4059.
  • 37
    Ross HM, Weber LW, Wang S, Piskun G, Dyall R, Song P, Takechi Y, Nikolic-Zugic J, Houghton AN, Lewis JJ. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 1997; 3: 21916.
  • 38
    Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi AR, Coyle JT. Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol 1999; 55: 17985.
  • 39
    Mincheff M, Altankova I, Zoubak S, Tchakarov S, Botev C, Petrov S, Krusteva E, Kurteva G, Kurtev P, Dimitrov V, Ilieva M, Georgiev G, et al. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer—changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 2001; 39: 12532.